OFFICIAL PUBLICATION OF

pdl.com.au

by its subsidiary APPco

AbbVie addresses hep C cash flow problems

Megan Haggan 04/05/2016

Viekira Pak

AbbVie Australia has announced the launch of a program to support timely patient access to their Hepatitis C medications VIEKIRA PAK and VIEKIRA PAK-RBV (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets with or without ribavirin) via community pharmacy. The two therapies are now available on the PBS for the treatment of genotype 1 chronic hepatitis C.1-3.

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

Teal questions pharmacist UTI programs

because much of the time, I think they’re giving antibiotics for things that are not UTIsPolitician says "I think" and…

Michael Hewson

Medics to ‘fight’ Doctor of Pharmacy title

Yet right now there are far too many reports from overseas of patients being unsure whether their care is from…

Michael Hewson

In scarce supply

I love a good joke.

Evan Nickols

Concurrent funding for aged care pharmacists and RMMRs needed

I understood that was to happen as a gradual changeover and not an abrupt cessation. Currently we do not have…

Jenny Gowan